Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that clinically relevant doses of venlafaxine extended-release block the norepinephrine transporter of the major depressive disorder patient's brain.
|
30649319 |
2019 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, NET gene rs5569 polymorphism could increase the risk of MDD, especially among Asians.
|
30292339 |
2018 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between T-182C, G1287A polymorphism in NET gene and suicidality in major depressive disorder in Chinese patients.
|
29703117 |
2018 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
NET impairment is evident in several clinically important conditions including major depressive disorder (MDD), panic disorder (PD), essential hypertension and the postural orthostatic tachycardia syndrome (POTS).
|
27046647 |
2017 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression.
|
28068779 |
2017 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms.
|
27631962 |
2017 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the relationship between the brain volume and these two polymorphisms of the SLC6A2 in MDD patients.
|
26960194 |
2016 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine.
|
27023264 |
2016 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study attempted to examine the relationship between polymorphisms of NET gene and MD.
|
26061302 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD.
|
25512257 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the separate effects and possible interactions between NET T-182C (rs2242446) and SERT 5-HTTLPR (rs4795541) polymorphisms on selective serotonin reuptake inhibitors (SSRI) treatment response and temperamental traits assessed by the Temperament and Character Inventory (TCI) in a clinical sample of subjects with major depressive disorder (MDD).
|
25739526 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD.
|
25827644 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET182C) polymorphisms are associated with susceptibility and treatment response in major depressive disorder (MDD).
|
25650523 |
2015 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
This study attempted to examine the relationship between polymorphisms of NET gene and MD.
|
26061302 |
2015 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 26 outpatients with treatment-resistant MDD and 27 matched healthy controls underwent magnetic resonance imaging and genotyping for six SNPs in monoaminergic genes [serotonin transporter (SLC6A4), norepinephrine transporter (SLC6A2), serotonin 1A and 2A receptors (HTR1A and HTR2A), catechol-O-methyltransferase (COMT), and brain-derived neurotrophic factor (BDNF)].
|
25990886 |
2015 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET182C) polymorphisms are associated with susceptibility and treatment response in major depressive disorder (MDD).
|
25650523 |
2015 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD.
|
25512257 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Conclusively, the present meta-analysis did not suggest a confirmed association between the T-182C polymorphism of the NET gene and MDD.
|
24374057 |
2014 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There were no relationships between lethality scores and SLC6A2 polymorphisms in suicidal MDD.
|
24655776 |
2014 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
There were no relationships between lethality scores and SLC6A2 polymorphisms in suicidal MDD.
|
24655776 |
2014 |
Major Depressive Disorder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The objective of this study was to characterise the DNA methylation state of the SLC6a2 gene promoter in patients with MDD and panic disorder.
|
24312678 |
2013 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Patients with MDD or panic disorder were not found to differ significantly from healthy controls in the pattern of methylation of the SLC6a2 gene promotor.
|
24312678 |
2013 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the NET T-182C and G1287A polymorphisms are not susceptibility factors for MDD.
|
23648227 |
2013 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed.
|
22727709 |
2012 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
252 unrelated Caucasian patients (f = 142; m = 110) with major depression were genotyped for NET and 5-HTT polymorphisms.
|
20588071 |
2010 |